Sunshine Heart's shares quadruple over heart pump; Quest Dx eyes profits from Merck partnership;

@FierceMedDev: While purchasers praise the FDA's device ID plan, members of the industry remain wary. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: Devicemaker B. Braun is moving to block Fresenius' purchase of Germany's Rhoen. More | Follow @DamianFierce

> Sunshine Heart ($SSH) has seen its shares quadruple in value as shareholders learn about its investigational heart pump, C Pulse Heart Assist. News

> Quest Diagnostics ($DGX) plans to gain from Merck's ($MRK) plan to end testing of an experimental osteoporosis drug early because of its success in preventing hip fractures, The Wall Street Journal reports. That's because the company gets royalties on future sales of the drug. Round-up

> The U.S. spinal implant market should hit close to $7 billion by 2018, Research and Markets concludes in a new report. Release

> Thermo Fisher Scientific ($TMO) has declared a quarterly cash dividend of 13 cents per share. Release

> Sen. Scott Brown (R-MA) is urging his colleagues to take up the medical device tax repeal bill passed by the House last month, saying the 2.3% charge will cost thousands of jobs. More

Biotech News

 @FierceBiotech: GSK, ‪Theravance‬ hit up regulators for approval of key asthma/COPD drug. More | Follow @FierceBiotech

 @JohnCFierce: Astrazeneca‬'s Link deal all about getting its new iMed - small, semi-virtual discovery unit - in gear. Wheelin/dealin. Item | Follow @JohnCFierce

 @RyanMFierce: BB Biotech rejected unsolicited proposal to take co private, says shares bested the Swiss mkt. Is that enough? Release | Follow @RyanMFierce

> Sanofi seals fate of Plavix R&D hub and others in layoff plan. Story

> AstraZeneca boosts virtual neuroscience unit with asset buys and Alzheimer's pact. News

> J&J unit strikes antibody drug deal with biotech Genmab. Article

> Upstart Sprout scores $20M round to revive fallen female libido drug. More

Pharma News

 @FiercePharma: Emerging-markets demand saves French plant where ‪Ipsen‬ makes primary care meds. News  | Follow @FiercePharma

> Forest independents immediately tell Carl Icahn no. News

> India to destroy 27M doses of BCG vaccine as shortages loom elsewhere. More

> China may not produce for Big Pharma long-term. Article

> 2,500 Sanofi jobs may be marched off patent cliff. Story

And Finally... Chemicals called phthalates, found in personal care products and on some medical devices, have been linked to an increased risk of diabetes in women, researchers at Brigham and Women's Hospital discovered. Story

 

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.